Mereo BioPharma (MREO)

• Market cap: $306M
• 1 day: -8.57%
• 5 days: -16.88%
• 1 month: 8.47%
• 3 months: 10.98%
• 6 months: -31.43%
• Year to date: -43.86%
• 1 year: -43.53%
• 5 years: -13.12%
• 10 years: -70.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Employees: 36